OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Klein on Gene Mutations in Prostate Cancer

March 11th 2017

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses gene mutations in patients with prostate cancer.

Dr. Siefker-Radtke on PD-L1 as a Biomarker in Bladder Cancer

March 10th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.

Dr. Choi on Evolution of RT in Prostate Cancer

March 10th 2017

Seungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses how radiation therapy has evolved for the treatment of patients with prostate cancer.

Dr. Gomella on Challenges Facing Genetic Testing in Prostate Cancer

March 10th 2017

Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses challenges facing genetic testing for patients with prostate cancer.

Dr. Linehan on Gene Mutations in Papillary Kidney Cancer

March 10th 2017

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses gene mutations in papillary kidney cancer.

Dr. Corn on Sequencing Agents for Patients With mCRPC

March 10th 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the agents available to treat patients with metastatic castration-resistant prostate cancer (mCRPC)

Dr. Chapin on Choosing Active Surveillance for Patients With Prostate Cancer

March 10th 2017

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the considering factors for a patient with prostate cancer to undergo active surveillance versus active treatment.

Dr. Grignani Discusses the Safety Profile of Trabectedin in Sarcoma

March 10th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.

Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

March 10th 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

Dr. Lonial Discusses Recent Updates in Multiple Myeloma

March 9th 2017

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Dr. Brown on the Development of Treatments for CLL

March 9th 2017

Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the development of the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) in the next 5 to 10 years.

Dr. Koyfman on Advancements in Technology and Safety of Treatments in Head and Neck Cancer

March 9th 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses advancements in technology and safety of treatments for patients with head and neck cancer.

Dr. McDermott on Lessons From the IMmotion150 Trial in RCC

March 8th 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.

Dr. Araujo on Importance of Bone-Targeting Agents in mCRPC

March 8th 2017

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of bone-targeting agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Dr. Jonasch on First- and Second-line Options for Patients With RCC

March 8th 2017

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the advancements in the first- and second-line settings for treating patients with renal cell carcinoma (RCC). Jonasch shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Dr. Crawford on PSA Testing for Prostate Cancer

March 8th 2017

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.

Dr. Kane on High-Penetrance Genetic Syndromes in Prostate Cancer

March 8th 2017

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.

Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast Cancer

March 8th 2017

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer

March 8th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.

Dr. Bastholt on Lenvatinib in Thyroid Cancer

March 7th 2017

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.